The last few weeks have started the same, and that’s with a list of penny stocks with potential catalysts. One of the exciting things about specific industries like biotech is that companies tend to pre-announce a date that news will come out in the future. Whether it’s something like a Prescription Drug User Fee Act (PDUFA) date with the FDA or new data readouts, there are many things to monitor. In most cases, biotech companies will give the public the timing of things like these.
The important part is deciding if upcoming events are potential bullish or bearish catalysts. As I’m sure many of you already know, biotech is a fickle area of the market. Companies can come out with positive data, but if one thing’s missed or came up short of expectations, a would-be optimistic report can become the reason penny stocks sell off. Last week we discussed 10 Top Penny Stocks To Watch With Potential Biotech Catalysts. Of those stocks discussed, some climbed to new September highs while others fell short. But the more you know, the better prepared you’ll be for what could be in store.
In this article, we’ll look at 5 penny stocks to watch this week with potential catalysts. Some have given specific dates, while others have shown a timeframe. After you get the lay of the land, then you can decide for yourself if they’re the best penny stocks to buy this week or if you should avoid them entirely.
Penny Stocks To Watch This Week
|1. Arbutus Biopharma (NASDAQ:ABUS)
|October 5, 2021 & October 7, 2021
|2. Kaleido Biosciences Inc. (NASDAQ:KLDO)
|October 5, 2021
|3. MannKind Corporation (NASDAQ:MNKD)
|October 5, 2021
|4. Adverum Biotechnologies Inc. (NASDAQ:ADVM)
|October 9, 2021
|5. Trevena Inc. (NASDAQ:TRVN)
|October 9, 2021
Penny Stocks To Watch On October 5:
The first name on this list of penny stocks to watch this week is Arbutus. We’ve discussed the company plenty of times. If you’re not familiar, however, let’s get you up to speed. Arbutus focuses on treatments for chronic infections, including hepatitis B, and new therapies for treating coronaviruses. A fair amount of attention has been on Arbutus versus Moderna, believe it or not. The two conflicted over Arbutus’s lipid formulations for nucleic acid delivery.
Last month, the European Patent Office said that its 069 patent related to lipid formulations was “Inventive” (valid). This was in line with the US Patent and Trademark Office’s response after it granted a notice of allowance in September. Moderna is moving forward with an appeal set for a hearing this month. However, if Arbutus is correct, it could open the doors for eligibility to receive royalties from Moderna’s COVID-19 vaccine sales.
What To Watch With ABUS Stock This Week
This week there are a few things to follow with Arbutus. The first comes on October 5th. The company presents at its first of 2 planned conferences. Arbutus will participate in a fireside chat at the Chardan Genetic Medicines Conference starting at 4:30 PM ET.
Later on this week, things could also put ABUS stock in focus. On October 7, the United States Court Of Appeals For The Federal Circuit will hear arguments from Arbutus and Moderna. So if ABUS stock or MRNA, for that matter, is on your list this week, keep this date in mind.
Kaleido Biosciences Inc.
Another one of the penny stocks to watch with events this week is Kaleido Biosciences. The company isn’t overly active in the stock market. However, around specific events, KLDO stock has experienced some volatility. Looking back at this summer, you’ll see a spike in June. This came just a few days after Kaleido’s presentation at the JMP Securities Life Sciences Conference. Whether or not the Conference was the official catalysts is to be seen. Fast-forward, and you’ll also see spikes when the company presented at other conferences this year, including the most recent in September at the Morgan Stanely Global Healthcare Conference.
The core point of focus with Kaleido has been on its Microbiome Metabolic Therapies (MMT) platform. Its KB295 treatment is also something traders have followed. It’s being studied in patients with mild-to-moderate ulcerative colitis. Meanwhile, the other side of Kaleido has put an emphasis on Long-Hauler COVID patients. The company’s KB109 is under evaluation for COVID-19.
What To Watch With KLDO Stock This Week
This week, the market could get a bit more clarity on where all of Kaleido’s treatments stand. On October 5, the company hosts an R&D presentation to discuss clinical data and pipeline advancement. The agenda includes corporate strategy, data from its non-IND study evaluating KB295, and preclinical data supporting the advancement of KB109 in COPD patients.
There are other companies like MannKind, which have previously announced pending updates. However, with this company, it didn’t give specific dates but only said October would be a month to keep in mind.
MannKind specializes in therapeutic products that patients inhale. Indications include endocrine and orphan lung diseases. Afrezza® Inhalation Powder is the company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States. MannKind is also preparing to manufacture Tyvaso DPI™ under a collaboration with United Therapeutics. Tyvaso DPI is under FDA review to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
What To Watch With MNKD Stock This Week
This week and this month could be important for MannKind. First, on October 5, the company participates at the Lytham Partners Fall Investor Conference. CEO Michael Castagna, PharmD, will discuss different facets of the company.
In addition, while a specific date wasn’t given, a September update discussed that FDA action on a New Drug Application (NDA) for Tyvaso DPI is expected this month. This comes after United Therapeutics submitted an NDA to the FDA seeking approval of Tyvaso DPI for treating adult patients with PAH and PH-ILD.
Penny Stocks To Watch On October 9:
Adverum Biotechnologies Inc.
Last week Adverum kicked off its month of industry presentations at the Retina Society Scientific Meeting on October 1. Considering that the presentation didn’t begin under 4 PM ET, there may be more details to digest heading into the start of the new week. What’s more, Adverum will present at two more conferences this month, the second of which comes this week. The company offers data from its Phase 2 INFINITY Trial using ADVM-022 in diabetic macular edema.
The company has been in and out of the spotlight over the last few months as it advances its gene therapy candidate. There’s also a plan to complete data analysis by year-end to develop a protocol and seek investigator and regulatory feedback on a Phase 2 clinical trial in wet AMD.
What To Watch With ADVM Stock This Week
This week, October 9th, will be the date to focus on. This is when the company delivers its Phase 2 Data on ADVM-022. Following this presentation, Adverum will also give results from its Phase 1 OPTIC Trial in neovascular AMD treated with ADVM-022. These won’t come until early next week at the ASRS Scientific Meeting (which we’ll update next week).
Trevena is another one of the penny stocks that’ve been in focus, thanks to COVID-19. Last week the company announced the results of its TRV027 proof-of-concept study in patients with the virus. Details showed a 92% probability that TRV027 has a potential beneficial impact on the primary endpoint of D-dimer levels. This is a biomarker associated with critical illness and mortality. The company also reported that treated patients had 12 days lower average hospital length of stay compared to placebo.
Other than TRV027, Trevena develops treatments for central nervous system disorders. This includes one approved product in the United States, OLINVYK® (oliceridine) injection. This is indicated in adults for acute pain management severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.
What To Watch With TRVN Stock This Week
This week, Trevena’s OLINVYK® will be a point of focus. Earlier in the year, two abstracts were accepted at ANESTHESIOLOGY® 2021. Both abstracts highlight safety data from the OLINVYK (oliceridine) injection program. The meeting is sponsored by the American Society of Anesthesiologists and will be shown on October 9th.
Penny Stocks To Watch This Week
There’s a lot to watch this week. Biotech penny stocks are part of that, and it’s essential to understand that companies with upcoming events aren’t “sure things” to see a move (up or down). However, at the very least, there could be some new information to factor in if any of these are on your list of penny stocks. Will that be the case this week?